Suppr超能文献

通过功能筛选鉴定白细胞介素-1为急性髓系白血病细胞增殖和疾病进展的关键介质

Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia.

作者信息

Carey Alyssa, Edwards David K, Eide Christopher A, Newell Laura, Traer Elie, Medeiros Bruno C, Pollyea Daniel A, Deininger Michael W, Collins Robert H, Tyner Jeffrey W, Druker Brian J, Bagby Grover C, McWeeney Shannon K, Agarwal Anupriya

机构信息

Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA.

Department of Cell, Developmental and Cancer Biology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA.

出版信息

Cell Rep. 2017 Mar 28;18(13):3204-3218. doi: 10.1016/j.celrep.2017.03.018.

Abstract

Secreted proteins in the bone marrow microenvironment play critical roles in acute myeloid leukemia (AML). Through an ex vivo functional screen of 94 cytokines, we identified that the pro-inflammatory cytokine interleukin-1 (IL-1) elicited profound expansion of myeloid progenitors in ∼67% of AML patients while suppressing the growth of normal progenitors. Levels of IL-1β and IL-1 receptors were increased in AML patients, and silencing of the IL-1 receptor led to significant suppression of clonogenicity and in vivo disease progression. IL-1 promoted AML cell growth by enhancing p38MAPK phosphorylation and promoting secretion of various other growth factors and inflammatory cytokines. Treatment with p38MAPK inhibitors reversed these effects and recovered normal CD34 cells from IL-1-mediated growth suppression. These results highlight the importance of ex vivo functional screening to identify common and actionable extrinsic pathways in genetically heterogeneous malignancies and provide impetus for clinical development of IL-1/IL1R1/p38MAPK pathway-targeted therapies in AML.

摘要

骨髓微环境中的分泌蛋白在急性髓系白血病(AML)中起着关键作用。通过对94种细胞因子进行体外功能筛选,我们发现促炎细胞因子白细胞介素-1(IL-1)在约67%的AML患者中引起髓系祖细胞的显著扩增,同时抑制正常祖细胞的生长。AML患者体内IL-1β和IL-1受体水平升高,沉默IL-1受体可导致克隆形成能力和体内疾病进展受到显著抑制。IL-1通过增强p38丝裂原活化蛋白激酶(p38MAPK)磷酸化并促进各种其他生长因子和炎性细胞因子的分泌来促进AML细胞生长。用p38MAPK抑制剂治疗可逆转这些效应,并使正常CD34细胞从IL-1介导的生长抑制中恢复。这些结果凸显了体外功能筛选对于识别基因异质性恶性肿瘤中常见且可作用的外在途径的重要性,并为AML中IL-1/IL1R1/p38MAPK途径靶向治疗的临床开发提供了动力。

相似文献

2
3
Chronic stress promotes acute myeloid leukemia progression through HMGB1/NLRP3/IL-1β signaling pathway.
J Mol Med (Berl). 2021 Mar;99(3):403-414. doi: 10.1007/s00109-020-02011-9. Epub 2021 Jan 7.
4
The TLK-ASF1 histone chaperone pathway plays a critical role in IL-1β-mediated AML progression.
Blood. 2024 Jun 27;143(26):2749-2762. doi: 10.1182/blood.2023022079.
6
Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML.
Front Immunol. 2020 Nov 26;11:595053. doi: 10.3389/fimmu.2020.595053. eCollection 2020.
9
GATA Factor-Dependent Positive-Feedback Circuit in Acute Myeloid Leukemia Cells.
Cell Rep. 2016 Aug 30;16(9):2428-41. doi: 10.1016/j.celrep.2016.07.058. Epub 2016 Aug 18.

引用本文的文献

2
Inflammatory signaling in the pathogenesis of acute myeloid leukemia.
Hemasphere. 2025 Aug 13;9(8):e70188. doi: 10.1002/hem3.70188. eCollection 2025 Aug.
3
Target practice: Opportunities for therapeutic intervention in CHIP and CCUS.
Blood Rev. 2025 Jul 25:101323. doi: 10.1016/j.blre.2025.101323.
4
Joint representation and visualization of derailed cell states with Decipher.
Genome Biol. 2025 Jul 23;26(1):219. doi: 10.1186/s13059-025-03682-8.
5
Metabolic reprogramming of fetal hematopoietic stem and progenitor cells by maternal obesity.
Front Hematol. 2025;4. doi: 10.3389/frhem.2025.1575143. Epub 2025 Apr 14.
7
Dual targeting of tumoral cells and immune microenvironment by blocking the IL-33/IL1RL1 pathway.
Nat Commun. 2025 Jul 14;16(1):6369. doi: 10.1038/s41467-025-61567-7.
9
Galectin-9 induces IL-1β production as a key inflammatory cytokine in the acute myeloid leukemia cell line (U937).
Res Pharm Sci. 2025 Mar 31;20(2):304-315. doi: 10.4103/RPS.RPS_234_23. eCollection 2025 Apr.
10
Mutant cooperates with or to drive distinct myeloid diseases and molecular outcomes.
Proc Natl Acad Sci U S A. 2025 May 20;122(20):e2415779122. doi: 10.1073/pnas.2415779122. Epub 2025 May 16.

本文引用的文献

1
IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models.
Blood. 2016 Dec 8;128(23):2683-2693. doi: 10.1182/blood-2015-11-679985. Epub 2016 Sep 12.
2
Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor-treated CML stem cells.
Blood. 2016 Dec 8;128(23):2671-2682. doi: 10.1182/blood-2015-11-679928. Epub 2016 Sep 12.
6
Therapeutically targeting SELF-reinforcing leukemic niches in acute myeloid leukemia: A worthy endeavor?
Am J Hematol. 2016 May;91(5):507-17. doi: 10.1002/ajh.24312. Epub 2016 Apr 4.
7
A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer.
Clin Cancer Res. 2016 Mar 1;22(5):1095-102. doi: 10.1158/1078-0432.CCR-15-1718. Epub 2015 Nov 18.
8
Cytokine overproduction and crosslinker hypersensitivity are unlinked in Fanconi anemia macrophages.
J Leukoc Biol. 2016 Mar;99(3):455-65. doi: 10.1189/jlb.3A0515-201R. Epub 2015 Oct 2.
10
BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein.
Blood. 2014 Nov 20;124(22):3260-73. doi: 10.1182/blood-2013-04-497040. Epub 2014 Oct 7.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验